Access

News and Views


Nature Medicine 9, 513 - 514 (2003)
doi:10.1038/nm0503-513

Cisplatin and the sensitive cell

Grover C. Bagby1 & Susan B. Olson1

  1. OSHU Cancer Institute, School of Medicine, Oregon Health and Science University, Portland, Oregon, USA e-mail: grover@ohsu.edu and e-mail: olsons@ohsu.edu


Epigenetic suppression of FANCF, a member of the Fanconi anemia gene family, is now implicated in some ovarian cancers. Might this suppression explain the sensitivity of such cancers to the cross-linking agent cisplatin (pages 568–574)?


Cancer cells are genetically unstable, often exhibiting complex karyotypes that include large deletions, insertions and unbalanced translocations of chromosomal material. Such cytogenetic findings typify the most aggressive and invasive malignancies.

MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

REVIEWS
Molecular views of recombination proteins and their control
Nature Reviews Molecular Cell Biology Review (01 Jun 2003)
 See all 14 matches for Reviews

NEWS AND VIEWS
FANCL, as in ligase
Nature Genetics News and Views (01 Oct 2003)
Fanconi anemia and breast cancer: what's the connection?
Nature Genetics News and Views (01 Apr 2001)
 See all 5 matches for News And Views

RESEARCH
The DNA crosslink-induced S-phase checkpoint depends on ATR–CHK1 and ATR–NBS1–FANCD2 pathways
The EMBO Journal Article (10 Mar 2004)
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Nature Medicine Article (01 May 2003)
 See all 13 matches for Research